Product Information Sheet for NR-20083

Influenza A (H1N1) 2009 Monovalent Vaccine

Catalog No. NR-20083

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Manufacturer:

Novartis Vaccines and Diagnostics, Limited, Liverpool, United Kingdom

Product Description:

Influenza A (H1N1) 2009 (pdm09) Monovalent Vaccine is a subunit (purified surface antigen) influenza virus vaccine prepared from A/California/7/2009 (H1N1)pdm09-like virus propagated in the allantoic cavity of embryonated chicken eggs. The virus was harvested and clarified by centrifugation and filtration prior to inactivation with betapropiolactone. The inactivated virus was concentrated and purified by zonal centrifugation. The surface antigens, hemagglutinin and neuraminidase, were obtained from the influenza virus particle by further centrifugation in the presence of nonylphenol ethoxylate, a process which removes most of the internal proteins. The nonylphenol ethoxylate was removed from the surface antigen preparation. Thimerosal, a mercury derivative used during manufacture, was removed by the purification steps to a trace amount (≤ 1 µg mercury per dose). Each 0.5 mL dose may also contain residual amounts of egg proteins (≤ 1 µg ovalbumin), polymyxin (≤ 3.75 µg), neomycin (≤ 2.5 µg), betapropiolactone (≤ 0.5 µg) and nonylphenol ethoxylate (≤ 0.015% w/v).

The hemagglutinin content was standardized according to U.S. Public Health Service requirements. Each 0.5 mL syringe contains the recommended 15 µg of hemagglutinin antigen.

Please note that this vaccine preparation is being released for research use only and not for human use. Vaccines produced for the 2009-2010 season are now past their expiration dates.

Material Provided:

Each syringe contains 0.5 mL of monovalent vaccine in phosphate-buffered saline.

Packaging/Storage:

NR-20083 contains a pre-filled 0.5 mL syringe. The product is provided on refrigerated bricks and should be stored at 2°C to 8°C immediately upon arrival. Do not freeze.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Influenza A (H1N1) 2009 Monovalent Vaccine, NR-20083."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Morse, D., et al. "Use of Influenza A (H1N1) 2009 Monovalent Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009."

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

MMWR Recomm. Rep. 58 (2009): 1-8. PubMed: 19713882.
2. Fiore, A. E., et al. "Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010." MMWR Recomm. Rep. 59 (2010): 1-62. PubMed: 20689501.
3. WHO Recommendations for Influenza Vaccines

Support Provided by NIAID

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898